JP2017514877A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514877A5
JP2017514877A5 JP2016567002A JP2016567002A JP2017514877A5 JP 2017514877 A5 JP2017514877 A5 JP 2017514877A5 JP 2016567002 A JP2016567002 A JP 2016567002A JP 2016567002 A JP2016567002 A JP 2016567002A JP 2017514877 A5 JP2017514877 A5 JP 2017514877A5
Authority
JP
Japan
Prior art keywords
methoxycyclopent
group
similarly
described below
same structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514877A (ja
JP6505131B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2015/051312 external-priority patent/WO2015170081A1/en
Publication of JP2017514877A publication Critical patent/JP2017514877A/ja
Publication of JP2017514877A5 publication Critical patent/JP2017514877A5/ja
Application granted granted Critical
Publication of JP6505131B2 publication Critical patent/JP6505131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567002A 2014-05-08 2015-05-05 イミダゾ［４，５−ｃ］キノリン−２−オン化合物および癌の処置におけるそれらの使用 Active JP6505131B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08
US61/990,232 2014-05-08
PCT/GB2015/051312 WO2015170081A1 (en) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
JP2017514877A JP2017514877A (ja) 2017-06-08
JP2017514877A5 true JP2017514877A5 (OSRAM) 2018-06-14
JP6505131B2 JP6505131B2 (ja) 2019-04-24

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567002A Active JP6505131B2 (ja) 2014-05-08 2015-05-05 イミダゾ［４，５−ｃ］キノリン−２−オン化合物および癌の処置におけるそれらの使用

Country Status (39)

Country Link
US (4) US9428503B2 (OSRAM)
EP (1) EP3140303B1 (OSRAM)
JP (1) JP6505131B2 (OSRAM)
KR (1) KR102013021B1 (OSRAM)
CN (1) CN106255692B (OSRAM)
AP (1) AP2016009532A0 (OSRAM)
AR (1) AR100340A1 (OSRAM)
AU (1) AU2015257456B2 (OSRAM)
CA (1) CA2946459C (OSRAM)
CL (1) CL2016002735A1 (OSRAM)
CR (1) CR20160523A (OSRAM)
CY (1) CY1120248T1 (OSRAM)
DK (1) DK3140303T3 (OSRAM)
DO (1) DOP2016000281A (OSRAM)
EA (1) EA031674B1 (OSRAM)
ES (1) ES2670416T3 (OSRAM)
HR (1) HRP20180697T1 (OSRAM)
HU (1) HUE037558T2 (OSRAM)
IL (1) IL248397B (OSRAM)
LT (1) LT3140303T (OSRAM)
MA (1) MA39960A (OSRAM)
MX (1) MX374401B (OSRAM)
NI (1) NI201600166A (OSRAM)
NO (1) NO2714752T3 (OSRAM)
NZ (1) NZ726042A (OSRAM)
PE (1) PE20170403A1 (OSRAM)
PH (1) PH12016502168B1 (OSRAM)
PL (1) PL3140303T3 (OSRAM)
PT (1) PT3140303T (OSRAM)
RS (1) RS57223B1 (OSRAM)
SG (1) SG11201609164VA (OSRAM)
SI (1) SI3140303T1 (OSRAM)
SM (1) SMT201800259T1 (OSRAM)
SV (1) SV2016005312A (OSRAM)
TN (1) TN2016000458A1 (OSRAM)
TR (1) TR201807101T4 (OSRAM)
TW (1) TWI662034B (OSRAM)
UY (1) UY36112A (OSRAM)
WO (1) WO2015170081A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2981365A1 (en) * 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as atm kinase inhibitors
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP4071174A1 (en) * 2016-02-15 2022-10-12 AstraZeneca AB Methods comprising fixed intermittent dosing of cediranib
WO2017162605A1 (en) * 2016-03-21 2017-09-28 Astrazeneca Ab Cinnolin-4-amine compounds and their use in treating cancer
US20190119270A1 (en) 2016-04-07 2019-04-25 Astrazeneca Ab N-Oxide Compound and Its Use in Treating Cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HUE054548T2 (hu) 2016-12-20 2021-09-28 Astrazeneca Ab Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
CN110167941B (zh) * 2017-01-09 2023-04-04 上海瑛派药业有限公司 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
WO2018153365A1 (zh) 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN115636833B (zh) * 2018-09-14 2024-11-29 苏州赞荣医药科技有限公司 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
EP3866785A1 (en) * 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
EP3935060B1 (en) * 2019-03-05 2023-11-15 Astrazeneca AB Fused tricyclic compounds useful as anticancer agents
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
CN114026097B (zh) * 2019-07-10 2024-02-23 上海瑛派药业有限公司 取代的吡唑并喹唑啉酮化合物及其应用
US20220354859A1 (en) * 2019-09-12 2022-11-10 Impact Therapeutics (Shanghai), Inc Substituted imidazoquinoxaline compounds and uses thereof
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
CN114980900A (zh) * 2020-01-13 2022-08-30 上海华禹生物科技有限公司 N2-喹啉或异喹啉取代的嘌呤衍生物在癌症治疗中的用途
JP2023539715A (ja) * 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN117015534A (zh) * 2021-02-03 2023-11-07 艾科思莱德制药公司 用于癌症疗法的双重atm和dna-pk抑制剂以及免疫治疗剂的组合
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20100311714A1 (en) * 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
EA020715B1 (ru) 2009-06-04 2015-01-30 Новартис Аг ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
AU2010299820A1 (en) * 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
EP2610406A1 (en) 2010-08-26 2013-07-03 Hitachi Construction Machinery Co., Ltd. Construction machine
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
RU2013130907A (ru) 2010-12-06 2015-01-20 Пирамал Энтерпрайзис Лимитед Замещенные имидазохинолиновые производные
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Similar Documents

Publication Publication Date Title
JP2017514877A5 (OSRAM)
JP2017107167A5 (OSRAM)
JP2017016753A5 (OSRAM)
JP2014179090A5 (OSRAM)
JP2017059339A5 (OSRAM)
JP2016204575A5 (OSRAM)
JP2015077594A5 (OSRAM)
JP2016526891A5 (OSRAM)
JP2017069240A5 (OSRAM)
JP2017528346A5 (OSRAM)
JP2017528401A5 (OSRAM)
JP2017179103A5 (OSRAM)
JP2016169268A5 (OSRAM)
JP2017509780A5 (OSRAM)
JP2016069397A5 (OSRAM)
JP2017203885A5 (OSRAM)
JP2017020017A5 (OSRAM)
JP2018538325A5 (OSRAM)
JP2016157119A5 (OSRAM)
JP2017533170A5 (OSRAM)
JP2017509782A5 (OSRAM)
JP2017075254A5 (OSRAM)
JP2016074795A5 (OSRAM)
JP2015174850A5 (OSRAM)
JP2017105890A5 (OSRAM)